Evorpacept (ALX148) + Trastuzumab + Chemotherapy (ASPEN-Breast)
ENHERTU®-experienced HER2-Positive Breast Cancer
Phase 2First patient in (FPI) planned for mid-2025
Key Facts
Indication
ENHERTU®-experienced HER2-Positive Breast Cancer
Phase
Phase 2
Status
First patient in (FPI) planned for mid-2025
Company
About ALX Oncology
ALX Oncology is dedicated to expanding treatment possibilities for cancer patients by developing synergistic approaches to optimize current and future standards of care. The company's core strategy revolves around its lead asset, evorpacept (ALX148), a next-generation CD47 inhibitor engineered to enhance anti-tumor activity of antibody-based therapies while minimizing hematologic toxicity. With a robust clinical pipeline spanning multiple high-value oncology indications and strategic partnerships with major pharmaceutical companies, ALX is positioned to advance the next generation of combination cancer treatments.
View full company profile